Search Results for: MARKET BRIEF The Market for


March 29, 2016

DRUG DEVELOPMENT – Don’t Overlook Key Preclinical Research March 29, 2016

Robert Wenslow, PhD, and Ann Newman, PhD, believe too often, drug discovery scientists, material scientists, and formulation specialists work in silos throughout the drug discovery process. Better integration of their efforts can reduce drug development schedules, risk, and overall costs that provide direct competitive business advantages.

July 9, 2014

BIOSIMILARS – The US Biosimilar Approval Pathway: Policy Precedes Science July 9, 2014

David Shoemaker, PhD, says the origin of the BPCIA had its roots in the Drug Price Competition and Patent Restoration Act of 1984 championed by Senators Waxman and Hatch, which has provided low-cost generic alternatives to prescription brand-name drugs for the three subsequent decades. What Congress failed to appreciate at the time was the current state of protein characterization science and consequently whether interchangeability could in fact be obtained or what level of biosimilarity was acceptable.